Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: ChondroT, a new herbal medication, consists of Angelica grosseserrata Maxim., Lonicera japonica Thunb., Angelica gigas Nakai, Clematis terniflora var. manshurica (Rupr.) Ohwi, and Phellodendron amurense Rupr. (6:4:4:4:3). Our previous studies have shown that ChondroT exhibits significant anti-arthritic and anti-inflammatory effects. In this study, we aimed to assess the toxicological safety assessment of ChondroT.
Methods: This study was designed to assess the safety of ChondroT after repeated oral administration. Male and female Sprague-Dawley rats were treated with ChondroT at oral doses of 0, 500, 1000, and 2000 mg/kg for 13 weeks. Mortality, clinical signs, body weight changes, food consumption, ophthalmological findings, urinalysis, hematological and blood-chemical parameters, necropsy findings, organ weights, and histological markers were recorded throughout the study period. Rats were also monitored for an additional 4 weeks to determine the recovery time.
Results: No death occurred and no significant changes in food consumption, ophthalmologic findings, and urinalysis were found. Although there were alterations in clinical signs, body weights, hematological parameters, blood-chemical parameters, necropsy findings, organ weights, and histological markers, they were not considered to be toxicologically significant.
Conclusions: The results suggest that the no-observed adverse effects level (NOAEL) was 2000 mg/kg/day for the test substance. ChondroT, a new complex herbal medication composed of five plants, can therefore be used safely at the NOAEL.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909520 | PMC |
| http://dx.doi.org/10.1186/s12906-019-2773-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.
JAMA Intern Med
September 2025
Bayer CC AG, Basel, Switzerland.
Importance: There is an unmet need for long-term, safe, effective, and hormone-free treatments for menopausal symptoms, including vasomotor symptoms (VMS) and sleep disturbances.
Objective: To evaluate the 52-week efficacy and safety of elinzanetant, a dual neurokinin-targeted therapy, for treating moderate to severe VMS associated with menopause.
Design, Setting, And Participants: OASIS-3 was a double-blind, placebo-controlled, randomized phase 3 clinical trial that was conducted at 83 sites in North America and Europe from August 27, 2021, to February 12, 2024, and included postmenopausal women aged 40 to 65 years who were seeking treatment for moderate to severe VMS (no requirement for a minimum number of VMS events per week).
Effect of time and local factors on the stability of hydrophilic self-tapping tissue-level implants: 1-year prospective study.
Int J Oral Implantol (Berl)
September 2025
Purpose: To evaluate changes in implant stability quotient values of hydrophilic tissue-level implants over time, and to investigate the influence of local factors on variations in these values.
Methods: Fifty tapered, self-tapping, tissue-level implants with a hydrophilic surface were placed and monitored for 12 months. Implant stability quotient values were recorded at the time of insertion (T0) and monthly thereafter for 12 months.
Protocol for a multisite study on the efficacy of transcranial direct current stimulation as an adjuvant to naming and spelling therapy in the treatment of oral and written naming in individuals with primary progressive aphasia.
Front Hum Neurosci
September 2025
Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, United States.
Primary progressive aphasia (PPA) is a neurological syndrome characterized by the gradual deterioration of language capabilities. Due to its neurodegenerative nature, PPA is marked by a continuous decline, necessitating ongoing and adaptive therapeutic interventions. Recent studies have demonstrated that behavioral therapies, particularly when combined with neuromodulation techniques such as transcranial direct current stimulation (tDCS), can improve treatment outcomes, including the long-term maintenance and generalization of therapeutic effects.
View Article and Find Full Text PDFThe Impact of Two Cordless Retraction Materials on Inflammatory Biomarkers Interleukin-1 Beta and Tumor Necrosis Factor-Alpha in Gingival Crevicular Fluid: An In-Vivo Study.
Cureus
August 2025
Department of Orthodontics, Kothiwal Dental College and Research Centre, Moradabad, IND.
Introduction: This study aimed to evaluate and compare the inflammatory responses of two cordless gingival retraction systems by assessing the levels of interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α) in gingival crevicular fluid (GCF). The objectives were to measure IL-1β and TNF-α levels before and after retraction using kaolin-based and polyvinyl acetate-based cordless gingival retraction materials at baseline, 1 h, and 24 h, and to compare the inflammatory profiles of these materials.
Materials And Methods: This in-vivo comparative study used a split-mouth design, with each of the 10 enrolled patients serving as their own control by receiving both kaolin-based paste (Traxodent®, Premier Dental Products, Plymouth Meeting, PA, USA) and polyvinyl acetate-based strip (Merocel®, Medtronic, Minneapolis, MN, USA) on different endodontically treated teeth requiring full-coverage crowns, thereby minimizing interindividual variability.
Impact of hyaluronic acid filler on lip impressions: a cheiloscopic study.
J Oral Biol Craniofac Res
August 2025
Department of Dentistry, Federal University of Maranhão, São Luís, Maranhão, Brazil.
Objectives: The objective of this study was to evaluate, through cheiloscopic analysis, the impact of hyaluronic acid (HA) lip augmentation on lip impressions. Eleven patients underwent HA injections and had their lips analyzed for thickness, morphological classification, commissure position, and lip impression types at three time points: before treatment (T1), one month after (T2), and three months after (T3). Lip thickness was measured using a digital caliper, and commissure position was classified based on standardized digital photographs.
View Article and Find Full Text PDF